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Abstract 
Background: The varicella zoster virus affects the central or peripheral nervous systems upon reactivation, especially 
when cell‑mediated immunity is impaired. Among varicella zoster virus‑related neurological syndromes, meningo‑
radiculitis is an ill‑defined condition for which clear management guidelines are still lacking. Zoster paresis is usu‑
ally considered to be a varicella zoster virus‑peripheral nervous system complication and treated with oral antiviral 
therapy. Yet in the literature, the few reported cases of herpes zoster with mild cerebral spinal fluid inflammation were 
all considered meningoradiculitis and treated using intravenous antiviral drugs, despite absence of systemic signs of 
meningitis. Nevertheless, these two clinical pictures are very similar.
Case presentation: We report the case of an alcohol‑dependent elderly Caucasian man presenting with left lower 
limb zoster paresis and mild cerebral spinal fluid inflammation, with favorable outcome upon IV antiviral treatment. 
We discuss interpretation of liquor inflammation in the absence of clinical meningitis and implications for the antiviral 
treatment route.
Conclusion: From this case report we suggest that varicella zoster virus‑associated meningoradiculitis should neces‑
sarily include meningitis symptoms with the peripheral neurological deficits and cerebral spinal fluid inflammation, 
requiring intravenous antiviral treatment. In the absence of (cell‑mediated) immunosuppression, isolated zoster pare‑
sis does not necessitate spinal tap or intravenous antiviral therapy.
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Background
Varicella zoster virus (VZV) is an exclusively human virus 
primarily causing chickenpox [1]. After a latency period 
in ganglionic neurons, VZV can reactivate and cause her-
pes zoster (HZ). The latter is favored by advanced age or 
immunosuppression [1–3] but can also occur in immu-
nocompetent individuals [4–8]. Reactivation of VZV may 
be accompanied by nervous system complications at both 
central (meningitis, encephalitis, vasculitis, cerebellitis, 
myelitis) and/or peripheral levels (cranial nerve pal-
sies, radiculitis) [2, 9]. The clinical symptoms, as well as 
complementary investigations (blood tests, imaging and 
electrophysiology), determine the neurological compli-
cations. Detecting VZV by real-time polymerase chain 
reaction (RT-PCR) in skin lesions confirms HZ diagno-
sis [10], while detection of VZV deoxyribonucleic acid 
(DNA) in cerebrospinal fluid (CSF) by RT-PCR or iden-
tification of intrathecal antiviral antibodies [2], indicates 
extension of the infection to the nervous system [11, 12]. 
Antiviral therapy is effective against VZV complications, 
specifically oral treatment (acyclovir or its pro-drug vala-
cyclovir with better oral absorption) in benign cases and 
intravenous (IV) acyclovir for severe conditions such as 
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ocular and central nervous system (CNS) complications, 
especially in immunosuppressed individuals [2, 3].
Here we report the case of an alcohol-dependent 
older man with zoster paresis in the context of a VZV-
associated meningoradiculitis. This clinical entity is not 
precisely defined in the literature and clear management 
guidelines about oral versus IV antiviral therapy are scant 
[13]. Clearly, preventing severe HZ neurological compli-
cations should be balanced by careful analysis of the most 
effective, efficient and least harmful treatment course. We 
suggest a definition of meningoradiculitis that is usable in 
clinical practice, including the choice of antiviral therapy. 
Alcohol- and age-induced cell-mediated immunity (CMI) 
dysfunction is identified as a plausible precipitating fac-
tor of VZV reactivation in our patient.
Case presentation
A 74-year-old Caucasian man was admitted to the Emer-
gency Room, addressed by his general practitioner for 
a 3-day history of progressive lower left limb weakness. 
He complained of a non-traumatic lumbar pain since 
10 days. Shortly after, a skin rash appeared on his lower 
back and extended to the left lower limb. He did not have 
fever or other new neurological complaints (in particu-
lar there was no urine or bowel retention or inconti-
nence). His medical history showed arterial hypertension 
(treated by an angiotensin converting enzyme and calcic 
inhibitor); alcohol dependence (with macrocytosis and 
lower limb polyneuropathy) and benign prostate hyper-
trophy managed using tamsulosin. Otherwise, he took 
Aspirin Cardio® and tramadol.
In addition to lower limb peripheral length-dependent 
abnormalities (ankle jerk areflexia, distal touch and vibra-
tion hypoesthesia), the initial neurological assessment 
revealed significant weakness in hip flexion (M3) and 
foot dorsiflexion (M2), absence of the left patellar reflex 
and disturbed position sense on the lower left limb. The 
Leri sign was positive on the left side. On general exami-
nation, clusters of small erythematous vesicular lesions 
were present on the anterior and internal sides of his 
left thigh and upper leg. A few similar lesions were also 
seen on the left part of the lower back. In summary, the 
clinical picture of the patient showed left L3–L4 sensory-
motor deficit associated with radicular zoster. A lumbar 
computerized tomography (CT)-scan excluded local 
compression (there was only degenerative lumbar disco-
pathy) and the skin smear was positive for VZV DNA but 
negative for Herpes simplex virus 1 and 2. The lumbar 
puncture (see Table 1), despite being traumatic, showed 
elevated white blood cells, almost exclusively lympho-
cytes, with high protein levels, blood brain barrier altera-
tion, but no local production of immunoglobulin. Viral 
activity was detected in the CSF (positive VZV RT-PCR). 
Electrophysiological studies confirmed left L3–L4 
motor and sensory radiculitis with axonotmesis and, as 
expected, a severe sensori-motor axonal lower limb poly-
neuropathy. Increased leucocytes and C-reactive protein 
evidenced mild systemic inflammation; the mean cor-
puscular volume and IgA levels were slightly increased 
whereas the thrombocyte rate was low (see Table  1 for 
more details and reference values). Liver function was 
normal, as well as thyroid stimulating hormone (TSH) 
and vitamin B12 and B9 levels. Viral (human immunode-
ficiency virus, HIV and hepatitis B virus, HBV), Borrelia 
burgdorferi and Treponema pallidum serology tests were 
all negative. At this point diagnosis of VZV meningo-
radiculitis was established.
It should be noted that the patient did not receive zos-
ter vaccine. He was treated within the first 24 h with oral 
acyclovir followed by IV acyclovir (10 mg/kg every 8 h/ 
day for 10 days) and showed mainly motor improvement 
(mild psoas and tibialis anterior paresis finally scored to 
M4). A few days after admission he developed posther-
petic neuralgia that improved with pregabaline and sub-
sequent amitriptyline and a fentanyl patch. Unfortunately 
analgesic overtreatment led to acute encephalopathy 
(normal blood tests, brain magnetic resonance imaging 
and electroencephalogram) that was reversed with dose 
adjustment. The patient was then transferred to a station-
ary neurorehabilitation center before returning home.
Discussion and conclusion
The patient described here had zoster paresis associated 
with mild inflammation and VZV activity in the CSF; 
leading to treatment mainly by IV acyclovir. The very few 
reported cases of VZV meningoradiculitis in the literature 
can be divided into two groups. The first corresponds to 
Table 1 Relevant abnormal blood and  cerebrospinal fluid 
results; normal ranges and units (in [])
Results [normal range and units]
Blood
 Leucocytes 12.3 [4.0–10.0 G/l]
 C‑reactive protein 18.4 [<5 mg/l]
 Thrombocytes 146 [150–350 G/l]
 Mean corpuscular volume 101 [80–100 fl]
 Immunoglobulin A 3.98 [1.03–3.30 g/l]
Cerebrospinal fluid
 Erythrocytes 139 [0/μl]
 White blood cells 139 [0–4/μl]
(99.5 % lymphocytes)
 Proteins 960 [150–450 mg/l]
 Varicella zoster virus polymerase 
chain reaction
Positive
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radiculitis without meningitis symptoms (a total of 5 cases 
of which only 2 were referred to as meningoradiculitis) 
[14–16]. The second group consists of patients with clini-
cally diagnosed meningitis (or encephalitis) associated 
with neurological peripheral deficits (only one of the two 
cases was explicitly mentioned as meningoradiculitis) [4, 
7]. Thus, the authors consider meningoradiculitis either 
to be a purely peripheral (parainfectious?) phenomenon 
[3, 15] or a CNS complication of VZV infection [2]. Sur-
prisingly, the CSF workup, when available, in these cases 
similarly displayed mild inflammation [4, 7, 14, 16]. Fur-
thermore, all patients with CSF results were treated by IV 
antiviral drug regardless of the presence of CNS symp-
toms or not, and without considering their immune sta-
tus. In contrast, the 3 cases reported by Chan et  al. (no 
CSF results available) only received supportive treatment 
(oral acyclovir was not yet available) [15] and yet the out-
come did not differ significantly from the other reported 
cases. Thus, there are obviously contradictions in the 
definition and management of VZV meningoradiculitis. 
It appears from the literature that clinicians tend to pre-
scribe IV antiviral treatment to patients with VZV radicu-
litis after performing CSF investigations, even if this 
choice does not clearly influence the prognosis.
If meningoradiculitis comprises clinical meningitis 
with peripheral nerve root involvement, then it should 
be treated, as with any other VZV-CNS complication, 
using IV antiviral drugs after spinal tap and other nec-
essary investigations [2, 6, 12]. Alternatively, we suggest 
considering radiculitis without obvious meningitis symp-
toms to be a VZV peripheral nervous system complica-
tion [15]. Such patients should therefore be exempt from 
CSF workup and, as for most cases in everyday clinical 
practice (contrary to published cases), orally treated with 
acyclovir with generally good outcome [2, 3]. The VZV 
peripheral nervous system complications are most prob-
ably underreported if we compare a rate of 3–5 % of her-
pes zoster [7, 15] to the very low number of reported 
cases (which are therefore not representative of daily 
practice as mentioned above). What diagnostic value 
therefore should inflammatory CSF (with direct or indi-
rect markers of VZV viral activity in the CSF) be given 
in VZV radiculitis, taking into account that inflammatory 
markers in the CSF are similar in patients with herpes-
related clinical meningitis or encephalitis to those with 
meningoradiculitis (see above) [12, 14, 16]? Moreover, 
mild inflammation in the CSF is reported in up to half of 
all patients with HZ and the presence of viral activity in 
the CSF does not necessarily establish a causal relation-
ship with neurological symptoms [3]. Along the same 
lines, in our patient, VZV RT-PCR was positive in the 
CSF without intrathecal production of immunoglobulin 
G (IgG) and local contamination from skin lesions in the 
lumbar region cannot be ruled out. Thus, CSF inflam-
mation should not be used apart from the clinical con-
text as a discriminating criterion between peripheral and 
central nervous system complications of VZV and should 
not solely determine the choice of the antiviral treat-
ment route. In the cases published, clinicians perhaps 
over-treated patients by prescribing IV acyclovir without 
clinically evident VZV-related CNS symptoms associated 
with the radiculitis. This was most probably done to pre-
vent severe neurological complications even if, as stated 
above, this reasoning cannot be fully justified.
None of the frequently reported immunosuppressive 
states (inflammatory rheumatic diseases, immunosup-
pressive treatments, HIV infection, etc.) triggering VZV 
reactivation [3] were found in our patient. However, he 
was in the most vulnerable age group (advanced age) for 
VZV reactivation and severity [3], due to age-dependent 
waning of VZV-related CMI [3, 17, 18]. CMI is important 
for the control of VZV infection. Similarly, he had signs 
of alcohol abuse (witnessed by macrocytosis, thrombope-
nia and increased serum IgA [19–21]), another condition 
that impairs CMI [21]. So in this case, in the absence of 
any other evident cause of immunosuppression, age and 
alcoholism were considered the factors lowering CMI 
and precipitating HZ. Nonetheless, clear guidelines do 
not exist for the choice of antiviral treatment in the con-
text of such subtle immunosuppression.
In conclusion, the patient had VZV cutaneous infec-
tion with radiculitis coincident with mild CSF inflamma-
tion. Reactivation of VZV was most probably precipitated 
by age- and alcohol-induced cell-mediated immunosup-
pression. He was diagnosed with meningoradiculitis and 
treated with IV acyclovir, despite the absence of clini-
cal meningitis. In available published cases, we did not 
find a consensual definition or management scheme for 
meningoradiculitis. The presence of CNS symptoms or 
abnormal CSF findings did not allow discrimination of 
severe from benign cases and these patients were gener-
ally IV treated. However, well-designed clinical trials are 
needed to review severity criteria for patients with VZV-
associated (meningo)-radiculitis, to study the efficiency 
of oral versus IV antiviral treatment and establish clear 
guidelines for management. Mild elevation of inflamma-
tory markers in the CSF is not specific or sensitive enough 
to establish a diagnosis of meningitis without evocative 
clinical symptoms. Therefore we suggest that until other-
wise demonstrated, the term “meningoradiculitis” should 
be used for and IV antiviral drugs prescribed to patients 
with clinical meningitis associated with neurological 
peripheral deficit in the context of VZV infection. Patients 
with isolated VZV radiculitis should be exempt from CSF 
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investigations and be given oral antiviral treatment, unless 
they are subject to any condition or pathology decreasing 
immunity, in particular CMI, in which case CSF workup 
and IV antiviral therapy may be necessary.
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